• Diagnostics Segment Revenue: $102.8 million in Q1 2025, including $25.1 million from assets being sold to LabCorp, compared to $126.9 million in Q1 2024.
• Diagnostics Segment Costs and Expenses: $126.8 million in Q1 2025, including $32.4 million related to assets being sold to LabCorp, compared to $161.3 million in Q1 2024.
• Operating Loss (Diagnostics Segment): $23.9 million in Q1 2025, compared to $34.4 million in Q1 2024.
• Pharmaceutical Segment Revenue: $47.1 million in Q1 2025, compared to $46.8 million in Q1 2024.
• RAYALDEE Revenue: $6.3 million in Q1 2025, compared to $6.9 million in Q1 2024.
• Net Loss: $67.6 million or $0.10 per share in Q1 2025, compared to $81.8 million or $0.12 per share in Q1 2024.
• Cash Position: Approximately $450 million in cash, cash equivalents, and restricted cash at the end of Q1 2025.
• Headcount Reduction: Reduced by 136 positions in Q1 2025, representing a 7% workforce reduction.
• Annualized Cost Savings: Estimated at approximately $19 million from actions initiated in Q1 2025.
• Total Revenue Guidance for 2025: Between $675 million and $685 million.
• Costs and Expenses Guidance for 2025: Between $825 million and $875 million, excluding nonrecurring expenses.

• Warning! GuruFocus has detected 6 Warning Signs with OPK.

Release Date: April 30, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

• OPKO Health Inc (NASDAQ:OPK) announced the sale of BioReference's Health Oncology and related clinical testing business to LabCorp, unlocking additional value in their Diagnostics segment.
• The company is advancing its dual-GLP-1/Glucagon agonist, OPK-88006, for the treatment of NASH, with promising preclinical results.
• OPKO Health Inc (NASDAQ:OPK) entered into a collaborative agreement with Entera Bio to develop an oral tablet form of OPK-88006, potentially enhancing its market reach.
• The company's Latin American business and EirGen Pharma continue to show revenue and profit growth.
• The Board approved a $100 million increase to the common stock repurchase program, indicating confidence in the company's valuation and financial health.

Negative Points

• The Diagnostics segment saw a revenue decrease to $102.8 million in Q1 2025 from $126.9 million in the same period of 2024, primarily due to previous transactions with LabCorp.
• OPKO Health Inc (NASDAQ:OPK) reported a net loss of $67.6 million for the first quarter of 2025, although this was an improvement from the previous year's loss.
• The company incurred $7.2 million in nonrecurring costs and expenses related to severance and facility closures.
• Revenue from RAYALDEE decreased slightly due to the challenging environment created by the Inflation Reduction Act.
• The company anticipates a nonrecurring other expense item related to a convertible debt exchange of approximately $90 million during the second quarter of 2025.

Q & A Highlights

Q: What are some possible explanations for the negative dynamics for NGENLA? Is it more likely competition, access issues, or something commercial related to Pfizer? A: Adam Logal, CFO, explained that the growth rates of prescriptions for both NGENLA and GENOTROPIN continue, suggesting the issue might be related to the commercial environment. They expect this to be a first-quarter-only event, which is why the guidance was only slightly reduced.

Q: Could you comment on why Pfizer withdrew their EU application for the adult setting and what are the plans for expansion into additional settings? A: Adam Logal, CFO, noted that Pfizer is focusing on expanding the label for NGENLA, particularly in pediatric indications due to the larger market size compared to adults. The decision to withdraw the EU application for adults was likely strategic to focus efforts on pediatric indications.

Q: Could you provide a rough timeline for the development program of the GLP-1/Glucagon tablet candidate? A: Adam Logal, CFO, stated that they expect to file an IND by the end of this year or early next year, with trial commencement thereafter. Results from a Phase I trial could be available by the end of 2026, with expected once-weekly dosing.

Q: What are the next steps for the subcutaneous obesity and MASH program, and how do you anticipate differentiating the oral formulation? A: Elias Zerhouni, President, explained that both the subcutaneous and oral formulations are in the pre-IND phase. The focus is on safety and dose range in Phase I trials. The oral formulation is once a day, while the subcutaneous is once a week, with a focus on liver diseases affected by fatty liver disease.

Q: Can you provide an update on the Epstein-Barr virus (EBV) trial and any efficacy signals that might de-risk the asset? A: Elias Zerhouni, President, mentioned that the trial involves 200 healthy volunteers in different cohorts to test adjuvants. The focus is on tolerability and safety, with immunogenicity measured through biomarkers, providing an idea of potential efficacy.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.